%0 Journal Article %1 harrison_global_2009 %A Harrison, Lee H %A Trotter, Caroline L %A Ramsay, Mary E %D 2009 %J Vaccine %K Africa Americas, Asia, Australia, Europe, Factors Geography, Humans, Incidence, Infections, Meningococcal Neisseria New Sahara, Serotyping, South Time Zealand, meningitidis, of the %P B51--63 %R 10.1016/j.vaccine.2009.04.063 %T Global epidemiology of meningococcal disease %U http://www.ncbi.nlm.nih.gov/pubmed/19477562 %V 27 Suppl 2 %X As reviewed in this paper, meningococcal disease epidemiology varies substantially by geographic area and time. The disease can occur as sporadic cases, outbreaks, and large epidemics. Surveillance is crucial for understanding meningococcal disease epidemiology, as well as the need for and impact of vaccination. Despite limited data from some regions of the world and constant change, current meningococcal disease epidemiology can be summarized by region. By far the highest incidence of meningococcal disease occurs in the meningitis belt of sub-Saharan Africa. During epidemics, the incidence can approach 1000 per 100,000, or 1\% of the population. Serogroup A has been the most important serogroup in this region. However, serogroup C disease has also occurred, as has serogroup X disease and, most recently, serogroup W-135 disease. In the Americas, the reported incidence of disease, in the range of 0.3-4 cases per 100,000 population, is much lower than in the meningitis belt. In addition, in some countries such as the United States, the incidence is at an historical low. The bulk of the disease in the Americas is caused by serogroups C and B, although serogroup Y causes a substantial proportion of infections in some countries and W-135 is becoming increasingly problematic as well. The majority of meningococcal disease in European countries, which ranges in incidence from 0.2 to 14 cases per 100,000, is caused by serogroup B strains, particularly in countries that have introduced serogroup C meningococcal conjugate vaccines. Serogroup B also predominates in Australia and New Zealand, in Australia because of the control of serogroup C disease through vaccination and in New Zealand because of a serogroup B epidemic. Based on limited data, most disease in Asia is caused by serogroup A and C strains. Although this review summarizes the current status of meningococcal disease epidemiology, the dynamic nature of this disease requires ongoing surveillance both to provide data for vaccine formulation and vaccine policy and to monitor the impact of vaccines following introduction.

@article{harrison_global_2009, abstract = {As reviewed in this paper, meningococcal disease epidemiology varies substantially by geographic area and time. The disease can occur as sporadic cases, outbreaks, and large epidemics. Surveillance is crucial for understanding meningococcal disease epidemiology, as well as the need for and impact of vaccination. Despite limited data from some regions of the world and constant change, current meningococcal disease epidemiology can be summarized by region. By far the highest incidence of meningococcal disease occurs in the meningitis belt of {sub-Saharan} Africa. During epidemics, the incidence can approach 1000 per 100,000, or 1\% of the population. Serogroup A has been the most important serogroup in this region. However, serogroup C disease has also occurred, as has serogroup X disease and, most recently, serogroup W-135 disease. In the Americas, the reported incidence of disease, in the range of 0.3-4 cases per 100,000 population, is much lower than in the meningitis belt. In addition, in some countries such as the United States, the incidence is at an historical low. The bulk of the disease in the Americas is caused by serogroups C and B, although serogroup Y causes a substantial proportion of infections in some countries and W-135 is becoming increasingly problematic as well. The majority of meningococcal disease in European countries, which ranges in incidence from 0.2 to 14 cases per 100,000, is caused by serogroup B strains, particularly in countries that have introduced serogroup C meningococcal conjugate vaccines. Serogroup B also predominates in Australia and New Zealand, in Australia because of the control of serogroup C disease through vaccination and in New Zealand because of a serogroup B epidemic. Based on limited data, most disease in Asia is caused by serogroup A and C strains. Although this review summarizes the current status of meningococcal disease epidemiology, the dynamic nature of this disease requires ongoing surveillance both to provide data for vaccine formulation and vaccine policy and to monitor the impact of vaccines following introduction.}, added-at = {2011-03-11T10:05:34.000+0100}, author = {Harrison, Lee H and Trotter, Caroline L and Ramsay, Mary E}, biburl = {https://www.bibsonomy.org/bibtex/268ac4de03a4ed8ae4df2a6b4aaf59139/jelias}, doi = {10.1016/j.vaccine.2009.04.063}, interhash = {9ebd07a58a3184ade83ca4d701f7c8c2}, intrahash = {68ac4de03a4ed8ae4df2a6b4aaf59139}, issn = {1873-2518}, journal = {Vaccine}, keywords = {Africa Americas, Asia, Australia, Europe, Factors Geography, Humans, Incidence, Infections, Meningococcal Neisseria New Sahara, Serotyping, South Time Zealand, meningitidis, of the}, month = jun, note = {{PMID:} 19477562}, pages = {B51--63}, timestamp = {2011-03-11T10:06:29.000+0100}, title = {Global epidemiology of meningococcal disease}, url = {http://www.ncbi.nlm.nih.gov/pubmed/19477562}, volume = {27 Suppl 2}, year = 2009 }